Shin Nippon Biomedical Laboratories, Ltd. Stock OTC Markets
Equities
SBLOF
JP3379950003
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
16.97 USD | -.--% |
|
-.--% | -.--% |
Sales 2025 * | 29.29B 187M | Sales 2026 * | 33.02B 211M | Capitalization | 54.04B 345M |
---|---|---|---|---|---|
Net income 2025 * | 3.78B 24.13M | Net income 2026 * | 5.26B 33.65M | EV / Sales 2025 * | 2.62 x |
Net Debt 2025 * | 22.77B 146M | Net Debt 2026 * | 25.46B 163M | EV / Sales 2026 * | 2.41 x |
P/E ratio 2025 * |
14.3
x | P/E ratio 2026 * |
10.3
x | Employees | 1,341 |
Yield 2025 * |
3.85% | Yield 2026 * |
4.11% | Free-Float | 46.34% |
![Extreme 16.97](/images/extremecours_fleche.png)
![Extreme 16.97](/images/extremecours_fleche.png)
![Extreme 16.97](/images/extremecours_fleche.png)
Managers | Title | Age | Since |
---|---|---|---|
Ryoichi Nagata
CEO | Chief Executive Officer | 65 | 81-08-31 |
Shinji Nitanda
DFI | Director of Finance/CFO | 55 | 02-04-30 |
Terumasa Hirai
CMP | Compliance Officer | - | 84-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ichiro Nagata
BRD | Director/Board Member | 38 | 17-03-31 |
Sales & Marketing | 64 | 02-10-31 | |
Ken Takanashi
COO | Chief Operating Officer | 60 | 02-11-30 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.62% | 47.96B | |
+1.67% | 42.45B | |
+44.47% | 41.47B | |
+28.04% | 31.6B | |
+21.54% | 28.63B | |
-6.35% | 28.03B | |
+52.62% | 14.56B | |
+48.94% | 14.14B | |
+3.68% | 12.58B |
- Stock Market
- Equities
- 2395 Stock
- SBLOF Stock